

Marjon H Cnossen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7926623/publications.pdf>

Version: 2024-02-01

127
papers

2,713
citations

185998

28
h-index

233125

45
g-index

131
all docs

131
docs citations

131
times ranked

2626
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. <i>Blood</i> , 2013, 122, 1954-1962.	0.6	188
2	Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1?. <i>J Neurosci</i> , 1997, 9, 458-464.		109
3	A prospective 10-year follow up study of patients with neurofibromatosis type 1. <i>Archives of Disease in Childhood</i> , 1998, 78, 408-412.	1.0	100
4	Age dependency of coagulation parameters during childhood and puberty. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2254-2263.	1.9	96
5	von Willebrand disease and aging: an evolving phenotype. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1066-1075.	1.9	87
6	Endocrinologic Disorders and Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. <i>Pediatrics</i> , 1997, 100, 667-670.	1.0	86
7	Paediatric arterial ischaemic stroke: functional outcome and risk factors. <i>Developmental Medicine and Child Neurology</i> , 2010, 52, 394-399.	1.1	85
8	Diagnosis and management of haemophilia. <i>BMJ</i> , 2012, 344, e2707-e2707.	3.0	82
9	Reduced prevalence of arterial thrombosis in von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 845-854.	1.9	79
10	Inhibitor development and mortality in non-severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1217-1225.	1.9	65
11	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. <i>Blood</i> , 2015, 125, 3006-3013.	0.6	62
12	Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease. <i>British Journal of Haematology</i> , 2015, 168, 553-556.	1.2	55
13	Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 763-769.	2.0	48
14	Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. <i>American Journal of Hematology</i> , 2019, 94, 575-584.	2.0	47
15	Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding. <i>American Journal of Hematology</i> , 2015, 90, 1142-1148.	2.0	46
16	Side effects of desmopressin in patients with bleeding disorders. <i>Haemophilia</i> , 2016, 22, 39-45.	1.0	46
17	Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. <i>British Journal of Haematology</i> , 2016, 174, 454-460.	1.2	46
18	CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 956-966.	1.9	45

#	ARTICLE	IF	CITATIONS
19	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. <i>Haemophilia</i> , 2015, 21, e185-92.	1.0	43
20	Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1437-1441.	1.9	43
21	Sickle cell disease: Clinical presentation and management of a global health challenge. <i>Blood Reviews</i> , 2019, 37, 100580.	2.8	42
22	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. <i>Blood Reviews</i> , 2018, 32, 265-271.	2.8	41
23	Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 468-478.	1.9	39
24	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. <i>Haematologica</i> , 2016, 101, 1159-1169.	1.7	39
25	Comorbidities associated with higher von Willebrand factor (^{VWF}) levels may explain the age-related increase of ^{VWF} in von Willebrand disease. <i>British Journal of Haematology</i> , 2018, 182, 93-105.	1.2	39
26	Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 in children <lt; or = 6 years and clinically suspected of having NF1. Neurofibromatosis team of Sophia Children's Hospital.. <i>Journal of Medical Genetics</i> , 1998, 35, 624-627.	1.5	37
27	In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI. <i>American Journal of Neuroradiology</i> , 2016, 37, 1727-1732.	1.2	37
28	Etiology and treatment of perinatal stroke; a role for prothrombotic coagulation factors?. <i>Seminars in Fetal and Neonatal Medicine</i> , 2009, 14, 311-317.	1.1	32
29	Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the ^{VERITAS}-Pro scale. <i>Haemophilia</i> , 2014, 20, 616-623.	1.0	32
30	Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2020, 18, 393.	2.3	30
31	Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. <i>EClinicalMedicine</i> , 2021, 32, 100726.	3.2	30
32	Current and Emerging Options for the Management of Inherited von Willebrand Disease. <i>Drugs</i> , 2017, 77, 1531-1547.	4.9	28
33	Analysis of current perioperative management with Haemate^Â P/Humate P^Â in von Willebrand disease: Identifying the need for personalized treatment. <i>Haemophilia</i> , 2018, 24, 460-470.	1.0	28
34	Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. <i>Haemophilia</i> , 2016, 22, e1-e10.	1.0	26
35	Clinically relevant differences between assays for von Willebrand factor activity. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2413-2424.	1.9	26
36	Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. <i>Thrombosis and Haemostasis</i> , 2013, 109, 440-449.	1.8	25

#	ARTICLE	IF	CITATIONS
37	Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. <i>British Journal of Haematology</i> , 2016, 172, 274-284.	1.2	25
38	Familial neurofibromatosis type 1 associated with an overgrowth syndrome resembling Weaver syndrome.. <i>Journal of Medical Genetics</i> , 1998, 35, 323-327.	1.5	24
39	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. <i>Haematologica</i> , 2017, 102, 1486-1493.	1.7	24
40	Diagnostic delay in neurofibromatosis type 1. <i>European Journal of Pediatrics</i> , 1997, 156, 482-487.	1.3	22
41	The "OPTI-CLOT" trial. <i>Thrombosis and Haemostasis</i> , 2015, 114, 639-644.	1.8	22
42	Oxygen gradient ektacytometry-derived biomarkers are associated with vasoocclusive crises and correlate with treatment response in sickle cell disease. <i>American Journal of Hematology</i> , 2021, 96, E29-E32.	2.0	21
43	Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	21
44	Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme. <i>Haemophilia</i> , 2019, 25, 162-169.	1.0	20
45	Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12488.	1.0	20
46	Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. <i>Thrombosis and Haemostasis</i> , 2018, 118, 514-525.	1.8	19
47	Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. <i>Blood Advances</i> , 2020, 4, 5025-5034.	2.5	19
48	Joint status of patients with nonsevere hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1126-1137.	1.9	17
49	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 152-160.	1.8	15
50	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. <i>American Journal of Hematology</i> , 2019, 94, E201-E205.	2.0	15
51	Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort study. <i>Haemophilia</i> , 2020, 26, e106-e115.	1.0	15
52	Relationship between neonatal screening results by HPLC and the number of β -thalassaemia gene mutations; consequences for the cut-off value. <i>Journal of Medical Screening</i> , 2011, 18, 182-186.	1.1	14
53	Achieving self-management of prophylactic treatment in adolescents: The case of haemophilia. <i>Patient Education and Counseling</i> , 2016, 99, 1179-1183.	1.0	14
54	Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease. <i>British Journal of Haematology</i> , 2018, 180, 432-442.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Sports participation and physical activity in patients with von Willebrand disease. <i>Haemophilia</i> , 2019, 25, 101-108.	1.0	14
56	Defining adherence to prophylaxis in haemophilia. <i>Haemophilia</i> , 2016, 22, e311-4.	1.0	13
57	In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1737-1746.	1.9	12
58	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. <i>Blood Advances</i> , 2019, 3, 4147-4154.	2.5	12
59	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. <i>Haemophilia</i> , 2016, 22, e36-8.	1.0	11
60	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 192-212.	1.0	10
61	The bleeding phenotype in people with nonsevere hemophilia. <i>Blood Advances</i> , 2022, 6, 4256-4265.	2.5	10
62	Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2196-2207.	1.9	9
63	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. <i>Lancet Haematology</i> , 2021, 8, e492-e502.	2.2	9
64	Treatment of patients with rare bleeding disorders in the Netherlands: Real-life data from the RBiN study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 833-844.	1.9	9
65	Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217069.	0.2	8
66	Optimization of home treatment in haemophilia: effects of transmural support by a haemophilia nurse on adherence and quality of life. <i>Haemophilia</i> , 2016, 22, 841-851.	1.0	8
67	Joint assessment in von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1465-1470.	1.8	8
68	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2018, 47, 621-629.	1.8	8
69	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 747-757.	1.8	8
70	Performance of factor IX extended half-life product measurements in external quality control assessment programs. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1874-1883.	1.9	8
71	Generic PROMIS item banks in adults with hemophilia for patient-reported outcome assessment: Feasibility, measurement properties, and relevance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12621.	1.0	8
72	Deep compartment models: A deep learning approach for the reliable prediction of time-series data in pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 934-945.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Perioperative replacement therapy in haemophilia B: An appeal to "more precise. Haemophilia, 2018, 24, 611-618.	1.0	7
74	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. BMJ Open, 2019, 9, e022719.	0.8	7
75	Outcome of Surgical Interventions and Deliveries in Patients with Bleeding of Unknown Cause: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1409-1416.	1.8	7
76	Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency. Blood Advances, 2021, 5, 2339-2349.	2.5	7
77	Patient-reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. Haemophilia, 2022, 28, 197-214.	1.0	7
78	Codon 24 (TAT>TAG) and Codon 32 (ATG>AGG) (Hb Rotterdam): Two Novel \pm Gene Mutations Associated with Mild β -Thalassemia Found in the Same Family After Newborn Screening. Hemoglobin, 2010, 34, 354-365.	0.4	6
79	Joint surgery in von Willebrand disease: a multicentre cross-sectional study. Haemophilia, 2016, 22, 256-262.	1.0	6
80	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P [®] /Humate P [®] treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305.	1.9	6
81	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613.	1.1	6
82	Health-related quality of life in infants, toddlers and young children with sickle cell disease. Pediatric Blood and Cancer, 2022, 69, e29358.	0.8	6
83	Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A. British Journal of Clinical Pharmacology, 2022, 88, 2757-2768.	1.1	6
84	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	1.9	6
85	Reliability and validity of a novel Haemophilia-specific Self-Efficacy Scale. Haemophilia, 2014, 20, e267-74.	1.0	5
86	Desmopressin response in hemophilia A patients with FVIII:C \leq 0.10 IU mL ⁻¹ . Journal of Thrombosis and Haemostasis, 2014, 12, 110-112.	1.9	5
87	Circadian Variation of Plasminogen-Activator-Inhibitor-1 Levels in Children with Meningococcal Sepsis. PLoS ONE, 2016, 11, e0167004.	1.1	5
88	Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen. Haemophilia, 2017, 23, 861-867.	1.0	5
89	Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. Pediatric Blood and Cancer, 2020, 67, e28588.	0.8	5
90	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1056-1065.	1.8	5

#	ARTICLE	IF	CITATIONS
91	Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 719-731.	1.9	5
92	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. <i>HemaSphere</i> , 2021, 5, e542.	1.2	5
93	Population pharmacokinetics of the von Willebrand factorâ€“factor VIII interaction in patients with von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 1513-1522.	2.5	5
94	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. <i>Thrombosis and Haemostasis</i> , 2021, 121, 731-740.	1.8	5
95	The group medical appointment (GMA) in haemophilia and von Willebrandâ€™s disease: a new development in outpatient paediatric care. <i>Haemophilia</i> , 2012, 18, 766-772.	1.0	4
96	A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol. <i>BMC Hematology</i> , 2016, 16, 21.	2.6	4
97	Positioning extended halfâ€“life concentrates for future use: a practical proposal. <i>Haemophilia</i> , 2018, 24, e369-e372.	1.0	4
98	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. <i>Haemophilia</i> , 2019, 25, 960-968.	1.0	4
99	Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4408-4420.	1.1	4
100	Sensorâ€“based gait analysis as a simple tool to measure gait in haemophilia patients. <i>Haemophilia</i> , 2017, 23, e355-e358.	1.0	3
101	Identifying Children with Hereditary Coagulation disorders (iCHEC): a protocol for a prospective cohort study. <i>BMJ Open</i> , 2018, 8, e020686.	0.8	3
102	Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1407-1416.	1.8	3
103	The oneâ€“stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in nonâ€“severe haemophilia A: Superiority or nonâ€“inferiority?. <i>Haemophilia</i> , 2020, 26, 916-922.	1.0	3
104	ADAMTSâ€“13 and bleeding phenotype in von Willebrand disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1331-1339.	1.0	3
105	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1-16.	1.6	3
106	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. <i>Haemophilia</i> , 2021, 27, 974-983.	1.0	3
107	Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. <i>Blood Advances</i> , 2021, 5, 4314-4325.	2.5	3
108	Quality of life and behavioral functioning in Dutch pediatric patients with hereditary spherocytosis. <i>European Journal of Pediatrics</i> , 2014, 173, 1217-1223.	1.3	2

#	ARTICLE	IF	CITATIONS
109	Self-infusion of prophylaxis: evaluating the quality of its performance and time needed. <i>Haemophilia</i> , 2016, 22, e214-7.	1.0	2
110	Gene Variations in the Protein C and Fibrinolytic Pathway: Relevance for Severity and Outcome in Pediatric Sepsis. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 036-047.	1.5	2
111	Pitfalls in the diagnosis of hemophilia severity: What to do?. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26276.	0.8	2
112	Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery. <i>BMJ Case Reports</i> , 2019, 12, bcr-2018-226812.	0.2	2
113	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. <i>Blood</i> , 2015, 126, 3510-3510.	0.6	2
114	In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 237-249.	0.8	2
115	Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study. <i>BMI Open</i> , 2022, 12, e049493.	0.8	2
116	Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. <i>Blood Advances</i> , 2022, 6, 5317-5326.	2.5	2
117	Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?. <i>Haemophilia</i> , 2022, , .	1.0	2
118	Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype. <i>HemaSphere</i> , 2022, 6, e718.	1.2	2
119	Defining patient value in haemophilia care. <i>Haemophilia</i> , 2018, 24, 516-518.	1.0	1
120	A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 880-885.	1.0	1
121	The Oxygenscan: A Rapid and Reproducible Test to Determine Patient-Specific, Clinically Relevant Biomarkers of Disease Severity in Sickle Cell Anemia. <i>Blood</i> , 2018, 132, 2360-2360.	0.6	1
122	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). <i>TH Open</i> , 2022, 06, e60-e69.	0.7	1
123	Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. <i>Haemophilia</i> , 2022, 28, 278-285.	1.0	1
124	Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study. <i>Haemophilia</i> , 2022, 28, 814-821.	1.0	1
125	Patients with Chromosome 11q Deletions Are Characterized by Inborn Errors of Immunity Involving both B and T Lymphocytes. <i>Journal of Clinical Immunology</i> , 0, , .	2.0	1
126	The association between desmopressin exposure, FVIII response and side effects. <i>Haemophilia</i> , 2021, 27, e506-e509.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia. BMJ Case Reports, 2021, 14, e238036.	0.2	0